Expression of topoisomerase II-α in triple negative breast cancer

Ivana Mrklić1, Zenon Pogorelić, Vesna Ćapkun

  • 1Departments of *Pathology, Forensic Medicine and Cytology †Pediatric Surgery ‡Nuclear Medicine, Split University Hospital Centre, School of Medicine, University of Split, Split, Croatia.

Insights

Triple negative breast cancer (TNBC) lacks targeted therapies. High topoisomerase II-alpha (topoIIα) expression in TNBC suggests anthracycline chemotherapy may be effective for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) presents a poor prognosis due to aggressive tumor biology and limited targeted therapy options.
  • Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negativity defines TNBC.
  • Topoisomerase II-alpha (topoIIα) is an intracellular target for anthracycline chemotherapy, with elevated expression noted in TNBC.

Purpose of the Study:

  • To investigate the prevalence of basal-like (BL) immunophenotype in TNBC.
  • To assess the correlation between BL immunophenotype, proliferation markers, and tumor characteristics.
  • To evaluate the expression of topoIIα in TNBC and its potential therapeutic implications.

Main Methods:

  • Immunohistochemical staining was performed on 83 TNBC patient samples (surgery dates: Jan 2003 - Dec 2009).
  • Markers analyzed included CK5/6, CK14, EGFR, Ki-67, and topoIIα.
  • Basal-like (BL) immunophenotype was defined by positivity for CK5/6, CK14, or EGFR.

Main Results:

  • 66.26% of TNBC cases exhibited the BL immunophenotype, significantly associated with higher mitotic count, BL morphology, histologic grade, and Ki-67 proliferation rate.
  • TopoIIα expression showed significant correlation with invasive ductal carcinoma NOS, higher mitotic count, histologic grade, and Ki-67.
  • A strong association was found between topoIIα expression and high proliferation rates (Ki-67).

Conclusions:

  • TNBC's lack of ER, PR, and HER2 expression limits targeted therapies, making chemotherapy the primary systemic treatment.
  • The observed topoIIα expression in TNBC suggests potential efficacy of anthracycline-based chemotherapy.
  • Targeting topoIIα could represent a viable therapeutic strategy for TNBC patients.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
DNA Topoisomerases02:02

DNA Topoisomerases

Topoisomerases are enzymes that relax overwound DNA molecules during various cell processes, including DNA replication and transcription. These enzymes regulate positive and negative DNA supercoiling without changing the nucleotide sequence. DNA overwinding in a clockwise direction results in positively supercoiled DNA, whereas underwinding in a counterclockwise direction produces negatively supercoiled DNA.
Types and Mechanism of action
Topoisomerases are divided into two main types.  Type I...